Drug Trial Radar · NCT00464269
Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures
Last checked: Nov 20, 2026Latest source record: Jul 21, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
400
Actual
Start
Sep 2007
Primary completion
Dec 2008
Study completion Jan 2009
Sponsor
- Lead sponsor
- UCB PharmaUCB
- Sponsor type
- Industry
- First posted
- Apr 23, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy and safety of Brivaracetam to support the submission file in the indication of adjunctive treatment in adolescents and adults with partial onset seizures.
Conditions
- Epilepsy
Interventions
PlaceboOther
* Active Substance: Placebo * Pharmaceutical Form: Film-coated tablet * Concentration: 2.5 mg, 10 mg and 25 mg * Route of Administration: Oral use
Brivaracetam 2.5 mgDrug
* Active Substance: Brivaracetam * Pharmaceutical Form: Film-coated tablet * Concentration: 2.5 mg * Route of Administration: Oral use
Brivaracetam 10 mgDrug
* Active Substance: Brivaracetam * Pharmaceutical Form: Film-coated tablet * Concentration: 10 mg * Route of Administration: Oral use
Brivaracetam 25 mgDrug
* Active Substance: Brivaracetam * Pharmaceutical Form: Film-coated tablet * Concentration: 25 mg * Route of Administration: Oral use
Primary outcomes
What the sponsor says the trial is designed to measure.
- Partial Onset Seizure (Type I) Frequency Per Week Over the 12-week Treatment PeriodTime frame: Baseline to 12-week Treatment Period
Locations
69 sites in 5 countries. Site status is shown where the registry gives one.
Site not named
Phoenix, Arizona
Site not named
Tucson, Arizona
Site not named
Little Rock, Arkansas
Site not named
Fresno, California
Site not named
Los Angeles, California
Site not named
Newport Beach, California
Site not named
Sacramento, California
Site not named
San Francisco, California
Site not named
Washington D.C., District of Columbia
Site not named
Atlanta, Georgia
Site not named
Augusta, Georgia
Site not named
Chicago, Illinois
Site not named
Springfield, Illinois
Site not named
Wichita, Kansas
Site not named
Lexington, Kentucky
Site not named
Louisville, Kentucky
Site not named
Baltimore, Maryland
Site not named
Bethesda, Maryland
Site not named
Burlington, Massachusetts
Site not named
Detroit, Michigan
Site not named
Grand Rapids, Michigan
Site not named
Saint Paul, Minnesota
Site not named
Tupelo, Mississippi
Site not named
Chesterfield, Missouri
Site not named
St Louis, Missouri
Site not named
New York, New York
Site not named
Rochester, New York
Site not named
Cincinnati, Ohio
Site not named
Columbus, Ohio
Site not named
Portland, Oregon
Site not named
Philadelphia, Pennsylvania
Site not named
Greenville, South Carolina
Site not named
Nashville, Tennessee
Site not named
Dallas, Texas
Site not named
Houston, Texas
Site not named
Salt Lake City, Utah
Site not named
Charlottesville, Virginia
Site not named
Richmond, Virginia
Site not named
Seattle, Washington
Site not named
Milwaukee, Wisconsin
Showing 40 of 69 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.